Veeva Systems: Infrastructure of Modern Drug Research. The S&P 500 Inclusion Provides a Boost.
The current valuation is again moderate with a P/E ratio under 20, supported by high customer retention and the successful CRM transition cycle to reach the 2030 revenue targets.
Reading Time: 2 minutes
Veeva Systems (VEEV) has positioned itself as the digital backbone of the global life sciences industry. The company boasts highly specialized industry expertise and a deeply integrated cloud architecture that has become incredibly important for research-oriented pharmaceutical companies. While general software providers often deliver only point solutions, Veeva covers the entire value chain from clinical development to commercial marketing. This structural embedding makes Veeva an essential player in enhancing efficiency and regulatory compliance...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
